Avelox (moxifloxacin, oral): Uses, Dosage & Side Effects

What it's for (Indications)

Treatment of various bacterial infections including: acute exacerbation of chronic bronchitis; acute bacterial sinusitis; community acquired pneumonia (especially when other antibiotics cannot be used or have failed); uncomplicated skin and skin structure infections (SSSI); complicated SSSI (including those that have responded to intravenous Moxifloxacin); mild to moderate pelvic inflammatory disease; complicated intra-abdominal infections; and plague.

Dosage Information

Type	Guideline
Standard	The recommended oral dose for adults is 400 mg once every 24 hours. The duration of therapy depends on the type of infection: * Community Acquired Pneumonia: 7 to 14 days * Uncomplicated Skin and Skin Structure Infections (SSSI): 7 days * Complicated SSSI: 7 to 21 days * Complicated Intra-Abdominal Infections: 5 to 14 days * Plague: 10 to 14 days * Acute Bacterial Sinusitis: 10 days * Acute Bacterial Exacerbation of Chronic Bronchitis: 5 days No specific dosage adjustment is typically required for patients with renal or hepatic impairment. Patients should complete the entire course of medication as prescribed by their doctor.

Type

Guideline

Standard

The recommended oral dose for adults is 400 mg once every 24 hours. The duration of therapy depends on the type of infection: * Community Acquired Pneumonia: 7 to 14 days * Uncomplicated Skin and Skin Structure Infections (SSSI): 7 days * Complicated SSSI: 7 to 21 days * Complicated Intra-Abdominal Infections: 5 to 14 days * Plague: 10 to 14 days * Acute Bacterial Sinusitis: 10 days * Acute Bacterial Exacerbation of Chronic Bronchitis: 5 days No specific dosage adjustment is typically required for patients with renal or hepatic impairment. Patients should complete the entire course of medication as prescribed by their doctor.

Safety & Warnings

Common Side Effects

Common side effects include: abdominal pain, bloating, abdominal discomfort, nausea, vomiting, headache, dizziness, and gastrointestinal upset.
More serious adverse reactions, often disabling and potentially irreversible, include: tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, QT prolongation (especially in patients with hypokalemia), exacerbation of myasthenia gravis, abnormal liver function tests (LFTs), superinfections, severe skin reactions, and risk of aortic aneurysm and dissection.
Clostridioides difficile-associated infection is also a potential adverse reaction.

Serious Warnings

Black Box Warning: WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS. Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects.
Patients should complete the entire course of medication to prevent recurrence of infection.
**Serious and Potentially Irreversible Adverse Reactions**: Moxifloxacin, a fluoroquinolone, is associated with disabling and potentially irreversible serious adverse reactions, including tendinitis, tendon rupture, peripheral neuropathy, and central nervous system effects.
**Tendinitis and Tendon Rupture**: Patients are advised to report any limb pain or inflammation immediately, as there is a risk of tendon inflammation or rupture.
**Peripheral Neuropathy**: May cause damage to nerves resulting in numbness, tingling, or pain.
**Central Nervous System Effects**: Patients at risk of seizures should discontinue this medication.
Other potential effects include headache and dizziness.
**Exacerbation of Myasthenia Gravis**: Use with caution in patients with myasthenia gravis, as it can worsen muscle weakness.
**QT Prolongation**: Use with caution, especially in patients with hypokalemia, as it can prolong the QT interval.
**Pseudomembranous Colitis**: Patients at risk of developing pseudomembranous (antibiotic associated) colitis should stay cautious if they experience persistent diarrhea.
**Hypersensitivity Reactions**: Severe hypersensitivity reactions are possible.
**Aortic Aneurysm and Dissection**: Increased risk has been reported.
**UV Exposure**: Patients are advised to avoid excessive UV exposure.
**Hepatic and Renal Impairment**: Patients should report signs of hepatic disease or renal impairment.
While no dosage adjustment is generally needed for renal or hepatic impairment, caution is advised.
**Ophthalmological Effects**: Consult an ophthalmologist if any effects on eyes are experienced.
**Heart Failure**: Use with caution in women and the elderly, particularly concerning heart failure.
**Storage**: Store at room temperature away from direct heat and sunlight.
Keep out of reach of children and pets.

How it Works (Mechanism of Action)

Moxifloxacin is a synthetic broad-spectrum antibacterial agent belonging to the fluoroquinolone class, specifically a fourth-generation fluoroquinolone. Its primary bactericidal mechanism of action involves the inhibition of two essential bacterial enzymes: DNA gyrase (also known as topoisomerase II) and topoisomerase IV. These enzymes play crucial, non-redundant roles in bacterial DNA replication, transcription, repair, and recombination processes, which are fundamental for bacterial survival and proliferation. DNA gyrase is responsible for introducing negative supercoils into bacterial DNA, a vital step that facilitates DNA replication and gene expression by maintaining the appropriate topological state of the DNA molecule. Topoisomerase IV, on the other hand, is primarily involved in the decatenation, or separation, of replicated bacterial chromosomes before cell division, ensuring accurate genetic segregation. By inhibiting both of these critical enzymes, moxifloxacin disrupts the integrity and processing of bacterial DNA, leading to irreversible double-stranded DNA breaks and the stabilization of enzyme-DNA cleavage complexes. This profound interference with fundamental bacterial DNA processes ultimately culminates in rapid bacterial cell death, signifying its bactericidal activity. The dual-targeting approach of moxifloxacin against both DNA gyrase and topoisomerase IV distinguishes it and contributes significantly to its potent efficacy against a wide range of susceptible gram-positive and gram-negative bacteria. This dual action also helps in mitigating the development of resistance that might arise from mutations affecting only one of the target enzymes, a common issue with earlier-generation fluoroquinolones. This concentration-dependent killing mechanism underscores its potent and broad-spectrum antibacterial activity.